A valid prescription requires a telehealth consultation with a licensed provider. No medication is dispensed without clinical evaluation.

BPC-157
Investigational Cytoprotective Pentadecapeptide


Compound Specifications
BPC-157
Investigational Cytoprotective Pentadecapeptide
BPC-157 is a 15-amino acid synthetic peptide sequence derived from human gastric juice protein fragments. In published preclinical research models, it has been investigated for potential biological mechanisms related to cellular migration, angiogenic signaling, and tissue recovery.
Preclinical laboratory models suggest BPC-157 may interact with angiogenic pathways, nitric oxide synthesis, and localized cellular migration involved in experimental tissue recovery.
Documented Therapeutic Benefits
Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Administer subcutaneously daily either systemically or near injured connective tissue.
Frequently Asked Clinical Questions
How quickly does BPC-157 work?
Most patients note substantial joint and digestive relief within 7 to 14 days of consistent administration.
Can BPC-157 be combined with Wolverine TB-500?
Healthcare providers often evaluate dual protocols combining BPC-157 and TB-500 based on their complementary investigational tissue pathways.
